Biotech · Private company
Urovant Sciences GmbH
Track this companyFree. Adds Urovant Sciences GmbH to your Dealase workspace and tells you when its record changes.
Clinical trials101 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- Tolterodine Tartrate ERPhase 3 · Overactive BladderClinicalTrials.gov · fetched Nov 12, 2026
- VibegronPhase 3 · Neurogenic Detrusor OveractivityClinicalTrials.gov · fetched Nov 12, 2026
- VibegronPhase 3 · Overactive BladderClinicalTrials.gov · fetched Nov 12, 2026
- URO-902Phase 2 · Overactive Bladder With Urge Urinary IncontinenceClinicalTrials.gov · fetched Nov 12, 2026
- VibegronPhase 2 · Irritable Bowel SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- hMaxi-KPhase 1 · Overactive BladderClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CICPHASE2_PHASE3 · RECRUITING · started Oct 12, 2022ClinicalTrials.gov NCT05491525 · fetched Nov 12, 2026
- Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)COMPLETED · started Oct 28, 2021ClinicalTrials.gov NCT05067478 · fetched Nov 12, 2026
- URO-902 in Female Subjects With Overactive Bladder and Urge Urinary IncontinencePHASE2 · COMPLETED · started Dec 16, 2019ClinicalTrials.gov NCT04211831 · fetched Nov 12, 2026
- Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic HyperplasiaPHASE3 · COMPLETED · started Sep 19, 2019ClinicalTrials.gov NCT04103450 · fetched Nov 12, 2026
- Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)PHASE3 · COMPLETED · started Mar 26, 2019ClinicalTrials.gov NCT03902080 · fetched Nov 12, 2026
- Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel SyndromePHASE2 · COMPLETED · started Dec 31, 2018ClinicalTrials.gov NCT03806127 · fetched Nov 12, 2026
- An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).PHASE3 · COMPLETED · started Jun 14, 2018ClinicalTrials.gov NCT03583372 · fetched Nov 12, 2026
- A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)PHASE3 · COMPLETED · started Mar 26, 2018ClinicalTrials.gov NCT03492281 · fetched Nov 12, 2026
- Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene TransferPHASE1 · COMPLETED · started Jan 1, 2013ClinicalTrials.gov NCT01870037 · fetched Nov 12, 2026
- Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor OveractivityPHASE1 · TERMINATED · started Apr 1, 2007ClinicalTrials.gov NCT00495053 · fetched Nov 12, 2026